{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T01:25:22Z","timestamp":1787275522152,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05840-6","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T01:18:11Z","timestamp":1787275091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological inhibition of CDK7 and CDK9 suppresses gastrointestinal\u00a0(colon)\u00a0cancer progression through modulation of stemness, epithelial-mesenchymal transition, and chemoresistance"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-2346","authenticated-orcid":false,"given":"Nidhi","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2848-589X","authenticated-orcid":false,"given":"Suriya","family":"Panneerselvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip B.","family":"Bharate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-737X","authenticated-orcid":false,"given":"Sai Balaji","family":"Andugulapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"5840_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678559","author":"AT Anshabo","year":"2021","unstructured":"Anshabo AT, Milne R, Wang S, Albrecht H (2021) CDK9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.678559","journal-title":"Front Oncol"},{"key":"5840_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0155013","volume":"11","author":"SA Balaji","year":"2016","unstructured":"Balaji SA, Udupa N, Chamallamudi MR et al (2016) Role of the drug transporter ABCC3 in breast cancer chemoresistance. PLoS ONE 11:e0155013. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0155013","journal-title":"PLoS ONE"},{"key":"5840_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052622","volume":"22","author":"\u00c1 Bartha","year":"2021","unstructured":"Bartha \u00c1, Gy\u0151rffy B (2021) TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci 22:2622. https:\/\/doi.org\/10.3390\/ijms22052622","journal-title":"Int J Mol Sci"},{"key":"5840_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118308","volume":"302","author":"S Bhulakshmi","year":"2026","unstructured":"Bhulakshmi S, Sharma N, Yaladanda N et al (2026) Design and synthesis of Entadamide A derivatives targeting breast cancer: insights into In silico, In vitro and In vivo models. Eur J Med Chem 302:118308. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118308","journal-title":"Eur J Med Chem"},{"key":"5840_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/neuonc\/noad143","volume":"26","author":"I Bhutada","year":"2024","unstructured":"Bhutada I, Khambati F, Cheng S-Y et al (2024) CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity. Neuro Oncol 26:70\u201384. https:\/\/doi.org\/10.1093\/neuonc\/noad143","journal-title":"Neuro Oncol"},{"key":"5840_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner JE, Hnisz D, Young RA (2017) Transcriptional addiction in cancer. Cell 168:629\u2013643. https:\/\/doi.org\/10.1016\/j.cell.2016.12.013","journal-title":"Cell"},{"key":"5840_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"5840_CR8","doi-asserted-by":"publisher","first-page":"37305","DOI":"10.18632\/ONCOTARGET.26468","volume":"9","author":"D Brisard","year":"2018","unstructured":"Brisard D, Eckerdt F, Marsh LA et al (2018) Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget 9:37305. https:\/\/doi.org\/10.18632\/ONCOTARGET.26468","journal-title":"Oncotarget"},{"key":"5840_CR9","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1200\/JCO.22.02777","volume":"41","author":"HA Burris","year":"2023","unstructured":"Burris HA, Moore MJ, Andersen J et al (2023) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 41:5482\u20135492. https:\/\/doi.org\/10.1200\/JCO.22.02777","journal-title":"J Clin Oncol"},{"key":"5840_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/J.CANLET.2021.03.012","volume":"507","author":"PM Chow","year":"2021","unstructured":"Chow PM, Chang YW, Kuo KL et al (2021) CDK7 inhibition by THZ1 suppresses cancer stemness in both chemona\u00efve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway. Cancer Lett 507:70\u201379. https:\/\/doi.org\/10.1016\/J.CANLET.2021.03.012","journal-title":"Cancer Lett"},{"key":"5840_CR11","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado J, Boiko S, Proia T et al (2020) AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res 26:922\u2013934. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1853","journal-title":"Clin Cancer Res"},{"key":"5840_CR12","doi-asserted-by":"publisher","unstructured":"Constantin TA, Varela-Carver A, Greenland KK et al (2023) The CDK7 inhibitor CT7001 (samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer 128(12):2326\u20132337. https:\/\/doi.org\/10.1038\/s41416-023-02252-8","DOI":"10.1038\/s41416-023-02252-8"},{"key":"5840_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70245","author":"P Danpanichkul","year":"2026","unstructured":"Danpanichkul P, Pang Y, Tothanarungroj P et al (2026) Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries. Cancer. https:\/\/doi.org\/10.1002\/cncr.70245","journal-title":"Cancer"},{"key":"5840_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50891-z","volume":"15","author":"R D\u00fcster","year":"2024","unstructured":"D\u00fcster R, Anand K, Binder SC et al (2024) Structural basis of Cdk7 activation by dual T-loop phosphorylation. Nat Commun 15:6597. https:\/\/doi.org\/10.1038\/s41467-024-50891-z","journal-title":"Nat Commun"},{"key":"5840_CR15","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1007\/s00018-021-03878-8","volume":"78","author":"S Egloff","year":"2021","unstructured":"Egloff S (2021) CDK9 keeps RNA polymerase II on track. Cell Mol Life Sci 78:5543\u20135567. https:\/\/doi.org\/10.1007\/s00018-021-03878-8","journal-title":"Cell Mol Life Sci"},{"key":"5840_CR16","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1242\/jcs.02718","volume":"118","author":"RP Fisher","year":"2005","unstructured":"Fisher RP (2005) Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 118:5171\u20135180. https:\/\/doi.org\/10.1242\/jcs.02718","journal-title":"J Cell Sci"},{"key":"5840_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1758834012469429","volume":"5","author":"KS Gunturu","year":"2013","unstructured":"Gunturu KS, Woo Y, Beaubier N et al (2013) Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther Adv Med Oncol 5:143\u2013151. https:\/\/doi.org\/10.1177\/1758834012469429","journal-title":"Ther Adv Med Oncol"},{"key":"5840_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/J.CANLET.2024.217191","volume":"604","author":"H Han","year":"2024","unstructured":"Han H, Yuan Y, Li C et al (2024) RNA-binding motif protein 28 enhances angiogenesis by improving STAT3 translation in hepatocellular carcinoma. Cancer Lett 604:217191. https:\/\/doi.org\/10.1016\/J.CANLET.2024.217191","journal-title":"Cancer Lett"},{"key":"5840_CR19","doi-asserted-by":"publisher","unstructured":"Han H, Gong C, Zhang Y et al (2025a) RBM30 recruits DOT1L to activate STAT1 transcription and drive immune evasion in hepatocellular carcinoma. Oncogene 44(41):3955\u20133973. https:\/\/doi.org\/10.1038\/s41388-025-03550-6","DOI":"10.1038\/s41388-025-03550-6"},{"key":"5840_CR20","doi-asserted-by":"publisher","unstructured":"Han H, Wang S, Ma L et al (2025b) ASH2L-K312-Lac stimulates angiogenesis in tumors to expedite the malignant progression of hepatocellular carcinoma. Adv Sci (Weinh) 12. https:\/\/doi.org\/10.1002\/ADVS.202509477","DOI":"10.1002\/ADVS.202509477"},{"key":"5840_CR21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41419-019-1831-7","volume":"10","author":"T Huang","year":"2019","unstructured":"Huang T, Ding X, Xu G et al (2019) CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2\/BCL-XL inhibitor ABT-263. Cell Death Dis 10:602. https:\/\/doi.org\/10.1038\/s41419-019-1831-7","journal-title":"Cell Death Dis"},{"key":"5840_CR22","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1128\/MCB.22.13.4622-4637.2002","volume":"22","author":"YK Kim","year":"2002","unstructured":"Kim YK, Bourgeois CF, Isel C et al (2002) Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol 22:4622\u20134637. https:\/\/doi.org\/10.1128\/MCB.22.13.4622-4637.2002","journal-title":"Mol Cell Biol"},{"key":"5840_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/annonc\/mdg106","volume":"14","author":"DY Kim","year":"2003","unstructured":"Kim DY, Kim JH, Lee S-H et al (2003) Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 14:383\u2013387. https:\/\/doi.org\/10.1093\/annonc\/mdg106","journal-title":"Ann Oncol"},{"key":"5840_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ygyno.2019.11.004","volume":"156","author":"J Kim","year":"2020","unstructured":"Kim J, Cho YJ, Ryu JY et al (2020) CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. Gynecol Oncol 156:211\u2013221. https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.004","journal-title":"Gynecol Oncol"},{"key":"5840_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020812","volume":"23","author":"L Kolloch","year":"2022","unstructured":"Kolloch L, Kreinest T, Meisterernst M, Oeckinghaus A (2022) Control of expression of key cell cycle enzymes drives cell line-specific functions of CDK7 in human PDAC cells. Int J Mol Sci 23:812. https:\/\/doi.org\/10.3390\/ijms23020812","journal-title":"Int J Mol Sci"},{"key":"5840_CR26","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1158\/1535-7163.MCT-23-0677","volume":"24","author":"A Kolodziejczyk","year":"2025","unstructured":"Kolodziejczyk A, Sicinski P (2025) Targeting transcriptional cyclin-dependent kinases in cancer. Mol Cancer Ther 24:1497\u20131510. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0677","journal-title":"Mol Cancer Ther"},{"key":"5840_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/13543776.2023.2195547","volume":"33","author":"M Kovalov\u00e1","year":"2023","unstructured":"Kovalov\u00e1 M, Baraka JP, Mik V et al (2023) A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018\u20132022). Expert Opin Ther Pat 33:67\u201387. https:\/\/doi.org\/10.1080\/13543776.2023.2195547","journal-title":"Expert Opin Ther Pat"},{"key":"5840_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000524977","volume":"11","author":"M Kudo","year":"2022","unstructured":"Kudo M (2022) Combination immunotherapy with anti-PD-1\/PD-L1 antibody plus anti-VEGF antibody may promote cytotoxic T lymphocyte infiltration in hepatocellular carcinoma, including in the noninflamed subclass. Liver Cancer (Basel) 11:185\u2013191. https:\/\/doi.org\/10.1159\/000524977","journal-title":"Liver Cancer (Basel)"},{"key":"5840_CR29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski N, Zhang T, Rahl PB et al (2014) Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511:616\u2013620. https:\/\/doi.org\/10.1038\/nature13393","journal-title":"Nature"},{"key":"5840_CR30","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1080\/15384101.2025.2485844","volume":"23","author":"C-F Lee","year":"2024","unstructured":"Lee C-F, Pienta KJ, Amend SR (2024) The involvement of cyclin-dependent kinase 7 (CDK7) and 9 (CDK9) in coordinating transcription and cell cycle checkpoint regulation. Cell Cycle 23:962\u2013974. https:\/\/doi.org\/10.1080\/15384101.2025.2485844","journal-title":"Cell Cycle"},{"key":"5840_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/J.CDTM.2019.08.006","volume":"5","author":"BB Li","year":"2019","unstructured":"Li BB, Wang B, Zhu CM et al (2019) Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy. Chronic Dis Transl Med 5:155\u2013169. https:\/\/doi.org\/10.1016\/J.CDTM.2019.08.006","journal-title":"Chronic Dis Transl Med"},{"key":"5840_CR32","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/cac2.70017","volume":"45","author":"M Li","year":"2025","unstructured":"Li M, Cao S, Xu R (2025) Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decades. Cancer Commun 45:774\u2013788. https:\/\/doi.org\/10.1002\/cac2.70017","journal-title":"Cancer Commun"},{"key":"5840_CR33","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.06535","author":"H Lu","year":"2015","unstructured":"Lu H, Xue Y, Yu GK et al (2015) Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism. Elife. https:\/\/doi.org\/10.7554\/eLife.06535","journal-title":"Elife"},{"key":"5840_CR34","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/CMDC.201700447","volume":"12","author":"U L\u00fccking","year":"2017","unstructured":"L\u00fccking U, Scholz A, Lienau P et al (2017) Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb\/CDK9 inhibitor for the treatment of cancer. ChemMedChem 12:1776. https:\/\/doi.org\/10.1002\/CMDC.201700447","journal-title":"ChemMedChem"},{"key":"5840_CR35","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/1538-7445.AM2017-984","volume":"77","author":"UT Luecking","year":"2017","unstructured":"Luecking UT, Scholz A, Kosemund D et al (2017) Abstract 984: identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops. Cancer Res 77:984\u2013984. https:\/\/doi.org\/10.1158\/1538-7445.AM2017-984","journal-title":"Cancer Res"},{"key":"5840_CR36","doi-asserted-by":"publisher","unstructured":"Lv M, Gong Y, Liu X et al (2023) CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties. Signal Transduct Target Ther 8:302. https:\/\/doi.org\/10.1038\/S41392-023-01555-9;SUBJMETA","DOI":"10.1038\/S41392-023-01555-9;SUBJMETA"},{"key":"5840_CR37","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3390\/ijms19061658","volume":"19","author":"J Machlowska","year":"2018","unstructured":"Machlowska J, Maciejewski R, Sitarz R (2018) The pattern of signatures in gastric cancer prognosis. Int J Mol Sci 19:1658. https:\/\/doi.org\/10.3390\/ijms19061658","journal-title":"Int J Mol Sci"},{"key":"5840_CR38","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1021\/acs.jmedchem.1c01171","volume":"65","author":"JJ Marineau","year":"2022","unstructured":"Marineau JJ, Hamman KB, Hu S et al (2022) Discovery of SY-5609: a selective, noncovalent inhibitor of CDK7. J Med Chem 65:1458\u20131480. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01171","journal-title":"J Med Chem"},{"key":"5840_CR39","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2174\/1874467215666220415131344","volume":"16","author":"S Mirzaei","year":"2022","unstructured":"Mirzaei S, Gholami MH, Zabolian A et al (2022) Resveratrol augments doxorubicin and cisplatin chemotherapy: a novel therapeutic strategy. Curr Mol Pharmacol 16:280\u2013306. https:\/\/doi.org\/10.2174\/1874467215666220415131344","journal-title":"Curr Mol Pharmacol"},{"key":"5840_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108712","volume":"163","author":"K Narendar","year":"2025","unstructured":"Narendar K, Narsimha K, Sharma N et al (2025) One-pot multi-component synthesis and biological evaluation of spirooxindole carbamate derivatives of major flavonoids isolated from Oroxylum indicum: identification of potent anti-proliferative leads active against hepatocellular carcinoma. Bioorg Chem 163:108712. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108712","journal-title":"Bioorg Chem"},{"key":"5840_CR41","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1172\/JCI64057","volume":"122","author":"KH Noh","year":"2012","unstructured":"Noh KH, Kim BW, Song K-H et al (2012) Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest 122:4077\u20134093. https:\/\/doi.org\/10.1172\/JCI64057","journal-title":"J Clin Invest"},{"key":"5840_CR42","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nchembio.2538","volume":"14","author":"CM Olson","year":"2018","unstructured":"Olson CM, Jiang B, Erb MA et al (2018) Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol 14:163\u2013170. https:\/\/doi.org\/10.1038\/nchembio.2538","journal-title":"Nat Chem Biol"},{"key":"5840_CR43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41392-025-02452-z","volume":"10","author":"M Otero-Rosales","year":"2025","unstructured":"Otero-Rosales M, \u00c1lvarez-Gonz\u00e1lez M, Pazos I et al (2025) CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer. Signal Transduct Target Ther 10:363. https:\/\/doi.org\/10.1038\/s41392-025-02452-z","journal-title":"Signal Transduct Target Ther"},{"key":"5840_CR44","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","volume":"9","author":"D Parry","year":"2010","unstructured":"Parry D, Guzi T, Shanahan F et al (2010) Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 9:2344\u20132353. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0324","journal-title":"Mol Cancer Ther"},{"key":"5840_CR45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1021\/jm5013984","volume":"58","author":"S Patel","year":"2015","unstructured":"Patel S, Cohen F, Dean BJ et al (2015) Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. J Med Chem 58:401\u2013418. https:\/\/doi.org\/10.1021\/jm5013984","journal-title":"J Med Chem"},{"key":"5840_CR46","doi-asserted-by":"publisher","first-page":"35445","DOI":"10.1039\/D5RA06548H","volume":"15","author":"M Pradeep Kumar","year":"2025","unstructured":"Pradeep Kumar M, Sarkar T, Durga Prasad V et al (2025) Pyrido-indole-one hybrids as potential anticancer agents against breast carcinoma: development of Ru(<scp>ii<\/scp>)-catalyzed annulation of indole-2-carboxamides, biological screening and molecular docking studies. RSC Adv 15:35445\u201335459. https:\/\/doi.org\/10.1039\/D5RA06548H","journal-title":"RSC Adv"},{"key":"5840_CR47","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41416-024-02810-8","volume":"131","author":"R Rahman","year":"2024","unstructured":"Rahman R, Rahaman MH, Hanson AR et al (2024) CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer. Br J Cancer 131:1092\u20131105. https:\/\/doi.org\/10.1038\/s41416-024-02810-8","journal-title":"Br J Cancer"},{"key":"5840_CR48","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.21873\/ANTICANRES.15416","volume":"41","author":"JP Ruff","year":"2021","unstructured":"Ruff JP, Kretz AL, Kornmann M et al (2021) The novel, orally bioavailable CDK9 inhibitor atuveciclib sensitises pancreatic cancer cells to TRAIL-induced cell death. Anticancer Res 41:5973\u20135985. https:\/\/doi.org\/10.21873\/ANTICANRES.15416","journal-title":"Anticancer Res"},{"key":"5840_CR49","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10555-020-09885-8","volume":"39","author":"GP Sava","year":"2020","unstructured":"Sava GP, Fan H, Coombes RC et al (2020a) CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev 39:805\u2013823. https:\/\/doi.org\/10.1007\/s10555-020-09885-8","journal-title":"Cancer Metastasis Rev"},{"key":"5840_CR50","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41388-019-1008-y","volume":"39","author":"GP Sava","year":"2020","unstructured":"Sava GP, Fan H, Fisher RA et al (2020b) ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942. Oncogene 39:651\u2013663. https:\/\/doi.org\/10.1038\/s41388-019-1008-y","journal-title":"Oncogene"},{"key":"5840_CR51","doi-asserted-by":"publisher","first-page":"7496","DOI":"10.1038\/sj.onc.1206950","volume":"22","author":"KW Scotto","year":"2003","unstructured":"Scotto KW (2003) Transcriptional regulation of ABC drug transporters. Oncogene 22:7496\u20137511. https:\/\/doi.org\/10.1038\/sj.onc.1206950","journal-title":"Oncogene"},{"key":"5840_CR52","doi-asserted-by":"publisher","first-page":"8667","DOI":"10.1021\/acs.jmedchem.6b00150","volume":"59","author":"YA Sonawane","year":"2016","unstructured":"Sonawane YA, Taylor MA, Napoleon JV et al (2016) Cyclin dependent kinase 9 inhibitors for cancer therapy. J Med Chem 59:8667\u20138684. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00150","journal-title":"J Med Chem"},{"key":"5840_CR53","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.6c00105","author":"NP Sree","year":"2026","unstructured":"Sree NP, Somarowthu T, Kuncha M et al (2026) Structure-guided discovery of a bis-pyridyl diamine-based dual 2 CDK7\/9 inhibitor with in vitro and in vivo antitumor efficacy in 3 glioblastoma multiforme. ACS Chem Neurosci. https:\/\/doi.org\/10.1021\/acschemneuro.6c00105","journal-title":"ACS Chem Neurosci"},{"key":"5840_CR54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41388-019-0953-9","volume":"39","author":"B Sun","year":"2020","unstructured":"Sun B, Mason S, Wilson RC et al (2020) Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene 39:50\u201363. https:\/\/doi.org\/10.1038\/s41388-019-0953-9","journal-title":"Oncogene"},{"key":"5840_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1745087","author":"A Szczepaniak","year":"2025","unstructured":"Szczepaniak A, Jasku\u0142a K, Zieli\u0144ska M, Godlewski J (2025) Transcriptional rewiring in cancer driven by POLR2A\/RPB1: mechanistic insights, non-coding RNA crosstalk, and therapeutic opportunities. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2025.1745087","journal-title":"Front Pharmacol"},{"key":"5840_CR56","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1021\/acs.biochem.2c00609","volume":"62","author":"MA Toure","year":"2023","unstructured":"Toure MA, Koehler AN (2023) Addressing transcriptional dysregulation in cancer through CDK9 inhibition. Biochemistry 62:1114\u20131123. https:\/\/doi.org\/10.1021\/acs.biochem.2c00609","journal-title":"Biochemistry"},{"key":"5840_CR57","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.chembiol.2025.03.001","volume":"32","author":"MA Toure","year":"2025","unstructured":"Toure MA, Motoyama K, Xiang Y et al (2025) Targeted degradation of CDK9 potently disrupts the MYC-regulated network. Cell Chem Biol 32:542-555.e10. https:\/\/doi.org\/10.1016\/j.chembiol.2025.03.001","journal-title":"Cell Chem Biol"},{"key":"5840_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/J.CMP.2026.04.001","volume":"19","author":"J Wang","year":"2026","unstructured":"Wang J, Zhu HR, Xu J et al (2026) Oncology drug resistance prediction tools: database infrastructure, algorithmic innovation, and clinical translation. Curr Mol Pharmacol 19:85\u201396. https:\/\/doi.org\/10.1016\/J.CMP.2026.04.001","journal-title":"Curr Mol Pharmacol"},{"key":"5840_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01301-7","volume":"20","author":"Y Wei","year":"2021","unstructured":"Wei Y, Li C, Bian H et al (2021) Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. Mol Cancer 20:5. https:\/\/doi.org\/10.1186\/s12943-020-01301-7","journal-title":"Mol Cancer"},{"key":"5840_CR60","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3390\/CANCERS14071714\/S1","volume":"14","author":"G Xie","year":"2022","unstructured":"Xie G, Zhu A, Gu X (2022) Converged DNA damage response renders human hepatocellular carcinoma sensitive to CDK7 inhibition. Cancers (Basel) 14:1714. https:\/\/doi.org\/10.3390\/CANCERS14071714\/S1","journal-title":"Cancers (Basel)"},{"key":"5840_CR61","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","volume":"39","author":"JF Zeidner","year":"2015","unstructured":"Zeidner JF, Karp JE (2015) Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. Leuk Res 39:1312\u20131318. https:\/\/doi.org\/10.1016\/j.leukres.2015.10.010","journal-title":"Leuk Res"},{"key":"5840_CR62","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41419-021-04344-w","volume":"12","author":"H Zeng","year":"2021","unstructured":"Zeng H, Yang H, Song Y et al (2021) Transcriptional inhibition by CDK7\/9 inhibitor SNS-032 suppresses tumor growth and metastasis in esophageal squamous cell carcinoma. Cell Death Dis 12:1048. https:\/\/doi.org\/10.1038\/s41419-021-04344-w","journal-title":"Cell Death Dis"},{"key":"5840_CR63","doi-asserted-by":"publisher","unstructured":"Zeng S, Lan B, Ren X et al (2022) CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. J Exp Clin Cancer Res 41(1):241. https:\/\/doi.org\/10.1186\/S13046-022-02443-W","DOI":"10.1186\/S13046-022-02443-W"},{"key":"5840_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02097-4","volume":"10","author":"T Zhan","year":"2025","unstructured":"Zhan T, Betge J, Schulte N et al (2025) Digestive cancers: mechanisms, therapeutics and management. Signal Transduct Target Ther 10:24. https:\/\/doi.org\/10.1038\/s41392-024-02097-4","journal-title":"Signal Transduct Target Ther"},{"key":"5840_CR65","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12943-019-1070-7","volume":"18","author":"J Zhang","year":"2019","unstructured":"Zhang J, Liu S, Ye Q, Pan J (2019) Transcriptional inhibition by CDK7\/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma. Mol Cancer 18:140. https:\/\/doi.org\/10.1186\/s12943-019-1070-7","journal-title":"Mol Cancer"},{"key":"5840_CR66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccell.2019.11.003","volume":"37","author":"H Zhang","year":"2020","unstructured":"Zhang H, Christensen CL, Dries R et al (2020) CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer. Cancer Cell 37:37-54.e9. https:\/\/doi.org\/10.1016\/j.ccell.2019.11.003","journal-title":"Cancer Cell"},{"key":"5840_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12575-025-00281-6","volume":"27","author":"Y Zou","year":"2025","unstructured":"Zou Y, Wan X, Zhou Q et al (2025) Mechanisms of drug resistance in hepatocellular carcinoma. Biol Proced Online 27:19. https:\/\/doi.org\/10.1186\/s12575-025-00281-6","journal-title":"Biol Proced Online"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05840-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05840-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05840-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T01:18:13Z","timestamp":1787275093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05840-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":67,"alternative-id":["5840"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05840-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Current study animal experiments were approved by the Institutional Animal Ethics Committee, approval number: IAEC-IICT-075\u20132025.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study is a preclinical in vitro and animal investigations and does not involve human participants or clinical trials. Hence, a clinical trial registration number is not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}